Chronic kidney disease trials recruiting in New Jersey

All Chronic kidney disease trials nationally

Cities in New Jersey

Recruiting trials in New Jersey

• A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
  NCT06830629 · Phase: Phase 2 · Ages: 18 Years to 68 Years · Sex: All (male and female) · New Jersey: Jersey City
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Eatontown
• A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
  NCT07222917 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Eatontown
• A Study of Luspatercept in People With Anemia
  NCT07725497 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Basking Ridge, Middletown, Montvale
• A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
  NCT06749457 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · New Jersey: Jersey City
• A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
  NCT04671771 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 90 Years · Sex: All (male and female) · New Jersey: Newark
• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
  NCT07107945 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · New Jersey: Hackensack, Neptune City
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Eatontown, Jersey City
• AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
  NCT07210021 · Phase: Not specified · Ages: 22 Years and older · Sex: All (male and female) · New Jersey: Eatontown
• An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
  NCT06278207 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Multiple Locations
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · New Jersey: Englewood, Freehold, Hackettstown, Morristown
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Eatontown, Jersey City
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Bridgewater
• Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
  NCT06190717 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 84 Years · Sex: All (male and female) · New Jersey: Pennington
• Rutgers University Study of the Genetics of Kidney Disease
  NCT07217535 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New Jersey: Piscataway
• SPYRAL GEMINI Pilot Study
  NCT06907147 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · New Jersey: Camden
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
  NCT07498335 · Phase: Phase 3 · Ages: 2 Years to 18 Years · Sex: All (male and female) · New Jersey: Neptune City